GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (AMEX:CVM) » Definitions » Shiller PE Ratio

CEL-SCI (CEL-SCI) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 1991. Start your Free Trial

What is CEL-SCI Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CEL-SCI Shiller PE Ratio Historical Data

The historical data trend for CEL-SCI's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Shiller PE Ratio Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CEL-SCI Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CEL-SCI's Shiller PE Ratio

For the Biotechnology subindustry, CEL-SCI's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Shiller PE Ratio falls into.



CEL-SCI Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CEL-SCI's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, CEL-SCI's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.14/131.7762*131.7762
=-0.140

Current CPI (Mar. 2024) = 131.7762.

CEL-SCI Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -2.750 100.560 -3.604
201409 -2.710 100.428 -3.556
201412 -3.500 99.070 -4.655
201503 -4.250 99.621 -5.622
201506 -1.500 100.684 -1.963
201509 -2.510 100.392 -3.295
201512 0.530 99.792 0.700
201603 -1.870 100.470 -2.453
201606 -0.780 101.688 -1.011
201609 -0.160 101.861 -0.207
201612 0.320 101.863 0.414
201703 -1.150 102.862 -1.473
201706 -0.530 103.349 -0.676
201709 -0.570 104.136 -0.721
201712 -0.530 104.011 -0.671
201803 -0.310 105.290 -0.388
201806 -0.360 106.317 -0.446
201809 -0.700 106.507 -0.866
201812 0.020 105.998 0.025
201903 -0.220 107.251 -0.270
201906 -0.370 108.070 -0.451
201909 -0.130 108.329 -0.158
201912 -0.160 108.420 -0.194
202003 -0.250 108.902 -0.303
202006 -0.270 108.767 -0.327
202009 -0.130 109.815 -0.156
202012 -0.210 109.897 -0.252
202103 -0.280 111.754 -0.330
202106 -0.250 114.631 -0.287
202109 -0.190 115.734 -0.216
202112 -0.200 117.630 -0.224
202203 -0.230 121.301 -0.250
202206 -0.230 125.017 -0.242
202209 -0.210 125.227 -0.221
202212 -0.180 125.222 -0.189
202303 -0.190 127.348 -0.197
202306 -0.190 128.729 -0.194
202309 -0.160 129.860 -0.162
202312 -0.140 129.419 -0.143
202403 -0.140 131.776 -0.140

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CEL-SCI  (AMEX:CVM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CEL-SCI Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (CEL-SCI) Business Description

Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
Executives
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Peter R Young director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
John Cipriano officer: Senior Vice President 8229 BOONE BLVD, SUITE 802, VIENNA VA 22182
Robert Eugene Watson director 245 N. HIGHLAND AVE NE, SUITE 230-296, ATLANTA GA 30307
Bruno Jean-marie Baillavoine director 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Eyal Talor officer: Chief Scientific Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Geert R Kersten director, officer: Chief Executive Officer 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Daniel H Zimmerman officer: Sr. Vice President, Research 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Patricia B Prichep officer: Sr. Vice President, Operations 8229 BOONE BLVD., SUITE 802, VIENNA VA 22182
Clara Maximilian De director, officer: President
C Richard Kinsolving director 8229 BOONE BLVD, STE 802, VIENNA VA 22182
Alexander G Esterhazy director 8229 BOONE BLVD, STE 802, VIENNA VA 22182